JPWO2019183587A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2019183587A5 JPWO2019183587A5 JP2020551273A JP2020551273A JPWO2019183587A5 JP WO2019183587 A5 JPWO2019183587 A5 JP WO2019183587A5 JP 2020551273 A JP2020551273 A JP 2020551273A JP 2020551273 A JP2020551273 A JP 2020551273A JP WO2019183587 A5 JPWO2019183587 A5 JP WO2019183587A5
- Authority
- JP
- Japan
- Prior art keywords
- optionally substituted
- item
- compound according
- alkyl
- phenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims description 363
- 125000000217 alkyl group Chemical group 0.000 claims description 167
- 125000004452 carbocyclyl group Chemical group 0.000 claims description 128
- 125000004404 heteroalkyl group Chemical group 0.000 claims description 115
- 125000000623 heterocyclic group Chemical group 0.000 claims description 97
- 125000001072 heteroaryl group Chemical group 0.000 claims description 73
- 125000003118 aryl group Chemical group 0.000 claims description 69
- 125000005843 halogen group Chemical group 0.000 claims description 54
- -1 3, 4-Di-Fluoro-Phenyl Chemical group 0.000 claims description 53
- 229910052760 oxygen Inorganic materials 0.000 claims description 34
- 229910052717 sulfur Inorganic materials 0.000 claims description 33
- 150000003839 salts Chemical class 0.000 claims description 25
- 239000011780 sodium chloride Substances 0.000 claims description 25
- 125000002947 alkylene group Chemical group 0.000 claims description 12
- 125000004474 heteroalkylene group Chemical group 0.000 claims description 12
- 239000008194 pharmaceutical composition Substances 0.000 claims description 11
- 125000004450 alkenylene group Chemical group 0.000 claims description 8
- 125000004419 alkynylene group Chemical group 0.000 claims description 8
- 229910052757 nitrogen Inorganic materials 0.000 claims description 6
- 230000001988 toxicity Effects 0.000 claims description 6
- 231100000419 toxicity Toxicity 0.000 claims description 6
- 201000010099 disease Diseases 0.000 claims description 5
- 230000002401 inhibitory effect Effects 0.000 claims description 5
- 125000004204 2-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C(OC([H])([H])[H])C([H])=C1[H] 0.000 claims description 4
- 125000004189 3,4-dichlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(Cl)C([H])=C1* 0.000 claims description 4
- 125000006275 3-bromophenyl group Chemical group [H]C1=C([H])C(Br)=C([H])C(*)=C1[H] 0.000 claims description 4
- 125000004179 3-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(Cl)=C1[H] 0.000 claims description 4
- 125000004180 3-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(F)=C1[H] 0.000 claims description 4
- 125000004207 3-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(OC([H])([H])[H])=C1[H] 0.000 claims description 4
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 claims description 4
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 claims description 4
- 125000004199 4-trifluoromethylphenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C(F)(F)F 0.000 claims description 4
- 102100010562 SCD5 Human genes 0.000 claims description 4
- 101700029333 SCD5 Proteins 0.000 claims description 4
- 125000004429 atoms Chemical group 0.000 claims description 4
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 claims description 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 4
- 206010029331 Neuropathy peripheral Diseases 0.000 claims description 3
- 125000004432 carbon atoms Chemical group C* 0.000 claims description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 3
- 201000001119 neuropathy Diseases 0.000 claims description 3
- 101700074430 SDH1 Proteins 0.000 claims description 2
- 239000000546 pharmaceutic aid Substances 0.000 claims description 2
- 102000004169 proteins and genes Human genes 0.000 claims description 2
- 108090000623 proteins and genes Proteins 0.000 claims description 2
- 101700066061 scd1 Proteins 0.000 claims description 2
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 8
- 125000006693 (C2-C9) heterocyclyl group Chemical group 0.000 claims 5
- IANQTJSKSUMEQM-UHFFFAOYSA-N Benzofuran Chemical compound C1=CC=C2OC=CC2=C1 IANQTJSKSUMEQM-UHFFFAOYSA-N 0.000 claims 2
- 229910052739 hydrogen Inorganic materials 0.000 description 49
- 150000001336 alkenes Chemical class 0.000 description 44
- 229910052799 carbon Inorganic materials 0.000 description 29
- 125000003342 alkenyl group Chemical group 0.000 description 14
- 210000004027 cells Anatomy 0.000 description 4
- 102100016914 SCD Human genes 0.000 description 3
- 108010028096 Stearoyl-CoA Desaturase Proteins 0.000 description 3
- SFLGSKRGOWRGBR-UHFFFAOYSA-N Phthalane Chemical compound C1=CC=C2COCC2=C1 SFLGSKRGOWRGBR-UHFFFAOYSA-N 0.000 description 2
- 125000000392 cycloalkenyl group Chemical group 0.000 description 2
- 125000000753 cycloalkyl group Chemical group 0.000 description 2
- 108010060159 Apolipoprotein E4 Proteins 0.000 description 1
- 102000003802 alpha-Synuclein Human genes 0.000 description 1
- 108090000185 alpha-Synuclein Proteins 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 210000003867 nerve cell Anatomy 0.000 description 1
- 210000002569 neurons Anatomy 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023211982A JP2024037913A (ja) | 2018-03-23 | 2023-12-15 | 化合物及びその使用 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862647308P | 2018-03-23 | 2018-03-23 | |
| US62/647,308 | 2018-03-23 | ||
| PCT/US2019/023737 WO2019183587A1 (fr) | 2018-03-23 | 2019-03-22 | Composés et leurs utilisations |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023211982A Division JP2024037913A (ja) | 2018-03-23 | 2023-12-15 | 化合物及びその使用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021519263A JP2021519263A (ja) | 2021-08-10 |
| JPWO2019183587A5 true JPWO2019183587A5 (fr) | 2022-03-30 |
Family
ID=67986384
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020551273A Pending JP2021519263A (ja) | 2018-03-23 | 2019-03-22 | 化合物及びその使用 |
| JP2023211982A Pending JP2024037913A (ja) | 2018-03-23 | 2023-12-15 | 化合物及びその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023211982A Pending JP2024037913A (ja) | 2018-03-23 | 2023-12-15 | 化合物及びその使用 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20220298168A1 (fr) |
| EP (1) | EP3768269A4 (fr) |
| JP (2) | JP2021519263A (fr) |
| KR (1) | KR20210005593A (fr) |
| CN (3) | CN118084801A (fr) |
| AU (1) | AU2019238326A1 (fr) |
| BR (1) | BR112020019191A2 (fr) |
| CA (1) | CA3094527A1 (fr) |
| EA (1) | EA202092225A1 (fr) |
| IL (1) | IL277502A (fr) |
| MA (1) | MA52092A (fr) |
| MX (1) | MX2020009942A (fr) |
| SG (1) | SG11202009280RA (fr) |
| WO (1) | WO2019183587A1 (fr) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018081167A1 (fr) | 2016-10-24 | 2018-05-03 | Yumanity Therapeutics | Composés et utilisations de ces derniers |
| CA3083000A1 (fr) | 2017-10-24 | 2019-05-02 | Yumanity Therapeutics, Inc. | Composes et utilisations de ces composes |
| KR20220007845A (ko) * | 2019-01-24 | 2022-01-19 | 유마니티 테라퓨틱스, 인크. | 화합물 및 이의 용도 |
| JP2022526890A (ja) * | 2019-03-22 | 2022-05-27 | ユマニティ セラピューティクス，インコーポレーテッド | 化合物及びその使用 |
| AU2022295990A1 (en) | 2021-06-18 | 2024-01-04 | Aligos Therapeutics, Inc. | Methods and compositions for targeting pd-l1 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR0012046A (pt) * | 1999-07-01 | 2002-05-14 | Ajinomoto Kk | Composto heterocìclico, composição farmacêutica, inibidor de ativação de ap-1 ou um inibidor da ativação de nf-kappab, inibidor da produção de citocina inflamatória, e, inibidor da produção de metaloprotease de matriz ou inibidor da expressão do fator de adesão de célula inflamatória |
| US6995162B2 (en) * | 2001-01-12 | 2006-02-07 | Amgen Inc. | Substituted alkylamine derivatives and methods of use |
| CA2528003A1 (fr) * | 2003-06-10 | 2004-12-23 | Kalypsys, Inc. | Composes carbonyle utilises comme inhibiteurs de l'histone desacetylase a des fins therapeutiques |
| MXPA06001480A (es) * | 2003-08-06 | 2006-05-15 | Pfizer Prod Inc | Compuestos de oxazol para el tratamiento de trastornos neurodegenerativos. |
| KR20060088537A (ko) * | 2003-09-06 | 2006-08-04 | 버텍스 파마슈티칼스 인코포레이티드 | Ａｔｐ-결합 카세트 수송체의 조절자 |
| WO2006022442A1 (fr) * | 2004-08-24 | 2006-03-02 | Santen Pharmaceutical Co., Ltd. | Nouveaux derives d’amides heterocycliques ayant une activite d’inhibition de la dihydroorotate deshydrogenase |
| JO2787B1 (en) * | 2005-04-27 | 2014-03-15 | امجين إنك, | Alternative amide derivatives and methods of use |
| EP2029138A1 (fr) * | 2005-06-03 | 2009-03-04 | Xenon Pharmaceuticals Inc. | Derives aminothiazole utilises en tant qu'inhibiteurs de la stearoyle-coa desaturase humaine |
| WO2008044767A1 (fr) * | 2006-10-13 | 2008-04-17 | Takeda Pharmaceutical Company Limited | Dérivé d'amine aromatique et utilisation de celui-ci |
| SG173409A1 (en) * | 2006-11-24 | 2011-08-29 | Ac Immune Sa | N-(methyl)-1h-pyrazol-3-amine, n-(methyl)-pyridin-2-amine and n-(methyl)-thiazol-2-amine derivatives for the treatment of diseases associated with amyloid or amyloid-like proteins, like e.g. alzheimers |
| WO2008123469A1 (fr) * | 2007-03-30 | 2008-10-16 | Japan Tobacco Inc. | Composé amide à six chaînons et son utilisation |
| GB0721419D0 (en) * | 2007-10-31 | 2007-12-12 | Smithkline Beecham Corp | Compounds |
| JP5523352B2 (ja) * | 2008-02-28 | 2014-06-18 | バーテックス ファーマシューティカルズ インコーポレイテッド | Ｃｆｔｒ修飾因子としてのへテロアリール誘導体 |
| NZ616097A (en) * | 2008-03-31 | 2015-04-24 | Vertex Pharma | Pyridyl derivatives as cftr modulators |
| GB0810913D0 (en) * | 2008-06-13 | 2008-07-23 | Smithkline Beecham Corp | Comppounds |
| EP2483264A1 (fr) * | 2009-10-01 | 2012-08-08 | Novartis AG | Dérivés de pyrazole qui modulent la stéaroyl-coa désaturase |
| JP6097998B2 (ja) * | 2010-12-16 | 2017-03-22 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | ロイコトリエン生成のビアリールアミドインヒビター |
| WO2012170931A2 (fr) * | 2011-06-10 | 2012-12-13 | Calcimedica, Inc. | Composés qui modulent le calcium intracellulaire |
| WO2014065860A1 (fr) * | 2012-10-24 | 2014-05-01 | The General Hospital Corporation | Composés 1,2,4,5-tétrazines fonctionnalisés destinés à être utilisés dans des réactions de couplage bioorthogonaux |
| TWI594975B (zh) * | 2013-04-24 | 2017-08-11 | 第一三共股份有限公司 | 二羧酸化合物 |
| WO2015054658A1 (fr) * | 2013-10-11 | 2015-04-16 | Sutro Biopharma, Inc. | Acides aminés modifiés comprenant des groupes fonctionnels de tétrazine, procédés de préparation et procédés d'utilisation associés |
| US20160223559A1 (en) * | 2015-02-02 | 2016-08-04 | The Regents Of The University Of California | Tetrazine-containing compounds and synthetic methods thereof |
| CN108473447A (zh) * | 2015-11-30 | 2018-08-31 | 勃艮第大学 | 制备官能化的1,2,4,5-四嗪化合物的方法 |
-
2019
- 2019-03-22 EA EA202092225A patent/EA202092225A1/ru unknown
- 2019-03-22 AU AU2019238326A patent/AU2019238326A1/en active Pending
- 2019-03-22 SG SG11202009280RA patent/SG11202009280RA/en unknown
- 2019-03-22 MA MA052092A patent/MA52092A/fr unknown
- 2019-03-22 MX MX2020009942A patent/MX2020009942A/es unknown
- 2019-03-22 CN CN202410214688.7A patent/CN118084801A/zh active Pending
- 2019-03-22 EP EP19771620.2A patent/EP3768269A4/fr active Pending
- 2019-03-22 CN CN202410169808.6A patent/CN118084800A/zh active Pending
- 2019-03-22 CN CN201980034106.4A patent/CN112312913B/zh active Active
- 2019-03-22 JP JP2020551273A patent/JP2021519263A/ja active Pending
- 2019-03-22 CA CA3094527A patent/CA3094527A1/fr active Pending
- 2019-03-22 KR KR1020207030056A patent/KR20210005593A/ko not_active Application Discontinuation
- 2019-03-22 BR BR112020019191-4A patent/BR112020019191A2/pt unknown
- 2019-03-22 WO PCT/US2019/023737 patent/WO2019183587A1/fr active Application Filing
-
2020
- 2020-09-22 IL IL277502A patent/IL277502A/en unknown
- 2020-09-22 US US17/028,778 patent/US20220298168A1/en active Pending
-
2023
- 2023-12-15 JP JP2023211982A patent/JP2024037913A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2005246964B2 (en) | Combinations comprising epothilones and pharmaceutical uses thereof | |
| JP2004511466A5 (fr) | ||
| JP2012530779A5 (fr) | ||
| JP2005525323A5 (fr) | ||
| JP2009523841A5 (fr) | ||
| JP2011505356A5 (fr) | ||
| JPWO2019195124A5 (fr) | ||
| JPWO2019183587A5 (fr) | ||
| JP2006520761A5 (fr) | ||
| RU2006104851A (ru) | Антагонисты мускариновых рецепторов ацетилхолина | |
| AU2002328921A1 (en) | Combinations comprising epothilones and pharmaceutical uses thereof | |
| JP2013504590A5 (fr) | ||
| TW201249858A (en) | Substituted indole derivatives | |
| JP2010535204A5 (fr) | ||
| JPWO2021262484A5 (fr) | ||
| JP2010535203A5 (fr) | ||
| TW570796B (en) | Use of derivatives of aryl(or heteroaryl)azolylcarbinols in the manufacture of a medicament for the treatment of neurogenic inflammation | |
| AU6277890A (en) | Slowly dissociating (tight binding) dopamine, serotonin or norepinephrine reuptake inhibitors as cocaine, amphetamine and phencyclidine antagonists | |
| JP2015502330A5 (fr) | ||
| US20210299136A1 (en) | Compositions And Methods For Inhibiting Type 1 Collagen Production | |
| AU2008203233B2 (en) | Combinations comprising epothilones and pharmaceutical uses thereof | |
| ZA200309898B (en) | Combinations comprising epothilones and pharmaceutical use thereof. | |
| JPWO2021200694A5 (fr) | ||
| JPWO2021252661A5 (fr) | ||
| AU778629B2 (en) | Cocaine receptor binding ligands |